Who are Urokinase thrombolysis's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Activase, Trasylol, Cyklokapron, Amicar, UPA-ECx2, Tranexamic Acid (IV).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/urokinase-thrombolysis.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Urokinase thrombolysis — Competitive Intelligence Brief

Urokinase thrombolysis (Urokinase thrombolysis) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic agent. Area: Cardiovascular.

phase 3 Fibrinolytic agent Plasminogen Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Urokinase thrombolysis (Urokinase thrombolysis) — Capital Medical University. Urokinase thrombolysis works by activating plasminogen to plasmin, which breaks down blood clots.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Urokinase thrombolysis TARGET	Urokinase thrombolysis	Capital Medical University	phase 3	Fibrinolytic agent	Plasminogen
Activase	ALTEPLASE	Roche	marketed		Plasminogen	1996-01-01
Trasylol	APROTININ	Bayer	marketed	Antifibrinolytic Agent	Plasminogen	1993-01-01
Cyklokapron	TRANEXAMIC ACID	Exela Pharma	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1986-01-01
Amicar	AMINOCAPROIC ACID	Epic Pharma Llc	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1964-01-01
UPA-ECx2	UPA-ECx2	Oregon Health and Science University	marketed		uPA (urokinase plasminogen activator)
Tranexamic Acid (IV)	Tranexamic Acid (IV)	Samsung Medical Center	marketed	Antifibrinolytic agent	Plasminogen / Plasmin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic agent class)

Capital Medical University · 1 drug in this class
Kedrion S.p.A. · 1 drug in this class
Supergene, LLC · 1 drug in this class
University of North Carolina, Chapel Hill · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Urokinase thrombolysis — Competitive Intelligence Brief. https://druglandscape.com/ci/urokinase-thrombolysis. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab